Sr. Manager/Associate Director, Commercial AI Engineer

Menarini Stemline; Bridgewater (MA); On-site; USD 125,000 - 185,000; Full time

Job summary

A leading company is seeking a Senior Manager/Associate Director, AI Engineer to innovate and optimize AI applications for their US Commercial Team. The role involves developing AI models, collaborating with teams, and driving efficiency in operations. This position offers a competitive salary and benefits in a dynamic environment focused on oncology advancements.

Benefits

Short- and Long-Term Incentive Programs

Fidelity 401(k) with company match

Anthem Premier PPO and HDHP insurance plans

Company paid Basic Life & AD&D insurance

Pre-tax FSA/HSA programs

Qualifications

• 2+ years of experience in AI and machine learning development.
• Experience implementing AI solutions in healthcare or pharmaceutical settings.

Responsibilities

• Develop and optimize AI models and algorithms for commercial team.
• Lead the development of AI applications for internal teams.
• Collaborate with contractors to enhance technical capabilities.

Skills

AI

Machine Learning

Data Engineering

Data Modeling

Python

SQL

Education

Bachelor's Degree in Computer Science

Job description

Overview

Senior Manager/Associate Director, Artificial Intelligence Engineer

Reports to AVP Omnichannel and Business Analytics

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

Responsibilities

Menarini-Stemline is seeking a highly skilled and motivated AI Engineer to join our commercialization team. The successful candidate will be responsible for developing, implementing, and optimizing artificial intelligence models and algorithms to drive innovation and efficiency supporting our US Commerical Team. This role will report to AVP, Omnichannel and Business Insights

Responsibilities

• Accelerate innovation by leading the development of groundbreaking AI applications / agents for the internal Menarini-Stemline team
• Design systems, write code, and implement AI-based enhancements to existing frameworks, tools, and processes
• Drive the development and execution of test plans, creation of test scripts, and thorough data validation processes.
• Provide Thought Leadership through providing guidance on how to use AI methods, algorithms, and models to make work more efficient
• Collaborate effectively with contractors to deliver technical enhancements.
• Stay abreast of the latest advancements in AI and machine learning technologies and apply them to Menarini-Stemline’s projects.
• Turn Ideas into Reality while partnering with the commercial team to identify key opportunities and deliver actionable AI products and insights.

Qualifications

• Minimum of a bachelor’s degree in computer science, Artificial Intelligence, Machine Learning, or a related discipline.
• 2+ years of experience in AI, machine learning, and large language models (LLMs) development and deployment.
• Strong aptitude and/or experience as a Data Engineer, Data Architect, or in Data Warehousing, Data Modeling, and Data Transformations.
• Strong understanding of data structures, algorithms, and software design principles
• Experience of successfully implementing AI solutions in a healthcare or pharmaceutical setting is preferred.
• Programming Languages: Proficiency in Python, SQL, and familiarity with Java or Scala
• AI and Automation: Knowledge of AI-driven tools for data pipeline automation. Ability to use GenAI or Agents to augment data engineering practices
• High degree of creativity and innovation in developing new approaches, processes and methodologies.
• Strong interpersonal skills and a consultative mindset, with the ability to develop strong partnerships and influence without authority.
• Strong organizational skills and time management; ability to manage diverse range of simultaneous projects.

Please note--this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.

Base Salary Range of $125,000 - $185,000 (plus package). Menarini Stemline offers generous compensation and benefits packages, including Short- and Long-Term Incentive Programs, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

#LI-PR1